ProCE Banner Activity

Anticipating Resistance in HABP/VABP: Strategies to Improve Empiric Regimens in the ICU

Multimedia

In this on-demand webcast from a live symposium at IDWeek 2022, expert faculty discuss strategies to anticipate resistance and improve timely and effective empiric HABP/VABP regimens in the ICU including use of rapid diagnostic testing, advanced antibiograms (eg, weight-incidence syndromic combination antibiograms, escalation antibiograms) and clinical prediction scores.

Released: November 16, 2022

Expiration: November 16, 2023

No longer available for credit.

Share

Faculty

Marion Elligsen

Marion Elligsen, BScPhm, MSc, RPh, ACPR

Practice-Based Researcher
Sunnybrook Research Institute
Antimicrobial Stewardship Pharmacy Lead
Department of Pharmacy
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada

Keith S. Kaye

Keith S. Kaye, MD, MPH

Chief
Division of Allergy, Immunology and Infectious Diseases
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

Andrew Shorr

Andrew Shorr, MD, MPH, MBA

Director, Pulmonary and Critical Care Medicine
Washington, DC

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Merck Sharp & Dohme, LLC

Target Audience

This program is intended for physicians, pharmacists, and other healthcare professionals who care for patients with HABP and VABP.

Learning Objectives

Faculty Disclosure

Primary Author

Marion Elligsen, BScPhm, MSc, RPh, ACPR

Practice-Based Researcher
Sunnybrook Research Institute
Antimicrobial Stewardship Pharmacy Lead
Department of Pharmacy
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada

Marion Elligsen, BScPhm, MSc, RPh, ACPR, has no relevant financial relationships to disclose.

Keith S. Kaye, MD, MPH

Chief
Division of Allergy, Immunology and Infectious Diseases
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

Keith S. Kaye, MD, MPH: consultant/advisor/speaker: Actavis, Allecra, Bayer, Carb-X, Cipla, Clarametyx, ContraFect, Cubist, Entasis, GlaxoSmithKline, Integrated Operations, Melinta, Merck, MicuRx, Nabriva, NS Nanotech, Pratek, Qpex, Shionogi, Spero, Utility, Venatorx, Xellia.

Andrew Shorr, MD, MPH, MBA

Director, Pulmonary and Critical Care Medicine
Washington, DC

Andrew Shorr, MD, MPH, MBA: consultant/advisor/speaker: Merck, Pfizer,Shionogi.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Program Medium

This program has been made available online.

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

 

Goal


The goal of this activity is to improve learners’ knowledge, competence, and performance in applying the latest practice guidance and data to provide appropriately broad empiric regimens for HABP/VABP in patients with risk factors for antimicrobial resistance.